Lack of evidence and safety concerns about the beginning and continued use of SGLT2 inhibitor during Ramadan fasting indicated an increased risk of volume depletion, hypoglycemia, and risk of diabetic ketoacidosis. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.